Health Diagnostic Laboratory asks court for permission to sell itself
Embattled clinical laboratory Health Diagnostic Laboratory (HDL) has filed a motion with the court overseeing its bankruptcy proceedings that asks for approval to sell itself. According to the company’s press release, it “intends to continue normal operations throughout the sale process, which is expected to maximize the value of the company and provide a platform for future growth.”
HDL’s president and CEO, Dr. Joseph McConnell, says numerous parties have already expressed interest in purchasing HDL.
Readers will recall HDL filed for Chapter 11 bankruptcy on June 7, 2015, approximately two months after the formal announcement that it had agreed to pay $47 million to settle allegations it provided kickbacks to physicians. According to the Richmond Times-Dispatch, HDL owes its thirty largest unsecured creditors $73.469 million.
A hearing on HDL’s motion is scheduled for July 14.
I reached out to HDL for comment, but did not hear back.
NYT uses Renaissance RX to discuss genetic testing fraud concerns
The New York Times uses Renaissance RX, the New Orleans-based pharmacogenetics laboratory that went from startup lab with a handful of employees to the darling of Louisiana politicians to the focus of a federal Medicare fraud investigation in just three years, as a backdrop for a brief discussion about the explosive growth in genetic tests nationwide, and how fraud may be playing a role.
Many thanks to Dr. Bruce Quinn over at Discoveries in Health Policy for alerting me to this article.
Theranos gets The Economist treatment
The Economist recently published a relatively superficial article about the opaque clinical laboratory company Theranos. I am still amazed how many articles are written about this company that has yet to demonstrate its proprietary methodology/technology can actually do what the company claims it can do.
Aurora Diagnostics teams up with University of Nevada School of Medicine
Aurora Diagnostics and the University of Nevada School of Medicine announced last week they have formed a public-private partnership that will serve to “enhance the anatomic pathology services available in northern Nevada and to serve as a platform for future clinical research partnerships.”